Key Points
- Ori Gutwerg, ANI Pharmaceuticals' SVP, sold 2,060 shares at an average price of $76.50 on March 3 for $157,590, leaving him with 84,782 shares (a 2.37% reduction).
- ANIP traded down to $75.29 (about -1.6%) with a market cap near $1.69B and a PE of 22.41; analysts' consensus is a “Moderate Buy” with an average price target of $103.43 (Guggenheim raised its target to $124).
- Institutions own roughly 76.05% of the stock, and several hedge funds (including Arrowstreet, Balyasny, Divisadero and UBS) recently built or increased large positions.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Ori Gutwerg sold 2,060 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00. Following the sale, the senior vice president directly owned 84,782 shares of the company's stock, valued at $6,485,823. This represents a 2.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
ANI Pharmaceuticals Stock Down 1.6%
ANIP traded down $1.24 during trading on Thursday, hitting $75.29. The company had a trading volume of 16,897 shares, compared to its average volume of 451,891. The company has a market capitalization of $1.69 billion, a PE ratio of 22.41 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The firm's 50-day moving average price is $79.92 and its 200 day moving average price is $86.11.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on ANIP. Zacks Research cut ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 6th. Guggenheim upped their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 price objective on the stock. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $103.43.
Get Our Latest Analysis on ANI Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Balyasny Asset Management L.P. grew its stake in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after buying an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new position in ANI Pharmaceuticals during the third quarter worth $21,454,000. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG raised its position in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after acquiring an additional 185,172 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
